ClinicalTrials.gg
RecruitingNCT07502976Updated Apr 6, 2026

Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia

An interventional study of Topical 2-Deoxy-D-ribose Hydrogel and Topical Minoxidil 5% Solution in Androgenic Alopecia, sponsored by Kasr El Aini Hospital. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Kasr El Aini Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Alopecia with a site in Egypt — 9 open to participants now, 9 under way, 1 of them phase 3. Alopecia · Egypt.

Planned enrollment
3rd of 21
60 · median 40
Started
2026
with 4 others
No phase
12 of 25
4 open now
Registered
20th of 25
by date
Lead sponsor
5 of 25
Kasr El Aini Hospital

Among the 25 studies in Alopecia with a site in Egypt, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2026, is one of 12 with no phase, and was the 20th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

9 of the 25 studies in Alopecia with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Alopecia with a site in Egypt, or all of them as a file.
02

Study summary

Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical minoxidil 5% solution in the treatment of mild to moderate androgenetic alopecia in adults aged 18 to 50 years. Sixty participants will be randomized into 2 treatment groups. The 2dDR group will apply 1 gram of topical 2dDR hydrogel once daily to the affected scalp areas for 6 months. The minoxidil group will apply topical minoxidil 5% solution to the affected scalp areas for 6 months according to sex-specific dosing in the protocol.

Participants will undergo clinical assessment, trichoscopic evaluation, and standardized scalp photography at baseline, Week 12, and Week 24. The study will also assess tissue vascular endothelial growth factor (VEGF) levels using scalp biopsy specimens obtained at baseline and after 3 months of treatment in both groups. Safety will be evaluated through adverse event monitoring and clinical scalp examination during follow-up visits.

Read the detailed description

Androgenetic alopecia (AGA) is a common androgen-dependent, genetically determined form of hair loss characterized by progressive shortening of the anagen phase, prolongation of telogen, and miniaturization of hair follicles. It commonly affects the frontal scalp, mid-scalp, and vertex in males, and typically presents as diffuse thinning over the crown with preservation of the frontal hairline in females. In addition to hormonal and genetic factors, inflammatory and oxidative stress-related mechanisms have been implicated in the pathogenesis of AGA.

Minoxidil is one of the currently approved treatments for AGA and is thought to improve hair growth through effects on scalp microcirculation, vascular endothelial growth factor (VEGF) expression, and direct stimulation of hair follicles. Recent preclinical studies have suggested that 2-Deoxy-D-ribose (2dDR), a deoxypentose sugar with pro-angiogenic properties, may stimulate angiogenesis through upregulation of VEGF and may promote hair regrowth. Based on these findings, this study is designed to compare topical 2dDR hydrogel with topical minoxidil 5% solution in patients with AGA and to investigate a possible mechanism of action through tissue VEGF assessment.

This study is a randomized controlled trial that will include 60 adult participants aged 18 to 50 years with mild to moderate AGA. Eligible male participants will have Hamilton-Norwood grades II to V, and eligible female participants will have Ludwig grades I to II. Participants will be recruited from the dermatology outpatient clinic of Cairo University Hospital. After informed consent and screening, eligible participants will be randomized into 1 of 2 treatment groups.

Participants in the 2dDR group will apply 1 gram (2 fingertip units) of topical 2dDR hydrogel once daily to targeted scalp areas for 6 months. Participants in the minoxidil group will apply topical minoxidil 5% solution to targeted scalp areas for 6 months, using 1 cc twice daily for men and once daily for women, as specified in the protocol.

Clinical evaluations will include medical history, family history, assessment of disease severity, trichoscopy, and standardized global scalp photography. Trichoscopic assessments will include hair density, terminal hair density, vellus hair density, average hair thickness, follicular unit density, percentage of hairs per follicular unit, and average follicular hairs per unit in predefined scalp areas. Standardized photographs will be obtained at baseline, Week 12, and Week 24 and assessed by blinded dermatologists using a 7-point global photographic scale. Participants will also complete patient global assessment and patient satisfaction evaluation at Week 12 and Week 24.

For biochemical assessment, scalp biopsy specimens will be obtained at baseline and after 3 months of treatment in both study groups to measure tissue VEGF levels by ELISA. In the 2dDR group, an additional biopsy will be obtained from a subset of participants after 3 months for histopathological evaluation of vascular proliferation, follicular thickness, and follicle count.

The primary outcome measures are the changes in terminal hair density and total hair density after 12 weeks of treatment, as well as the change in tissue VEGF levels from baseline to Week 12. Secondary outcomes include changes in terminal and total hair density at Week 24, physician-rated global photographic assessment, patient global assessment, patient satisfaction, safety based on adverse events and scalp examination, and correlation of treatment response with clinical and demographic variables.

03

Conditions studied

  • Androgenic Alopecia

Browse trials for

Keywords

  • Male Pattern Hair Loss
  • Female Pattern Hair Loss
  • 2-Deoxy-D-ribose
  • 2dDR Hydrogel
  • Hair Loss
  • Trichoscopy
  • VEGF
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 50 years.
  • Male and female patients with androgenetic alopecia.
  • Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V in males and Ludwig scale I to II in females.
  • Ability and willingness to provide written .

Exclusion criteria

Exclusion Criteria:

  • Other types of hair loss, including inflammatory or scarring alopecia.
  • Psoriasis.
  • Inflammatory scalp dermatoses.
  • History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
  • Chemotherapy during the last 5 years.
  • Pregnancy.
  • Lactation.
  • Bleeding disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Topical 2-Deoxy-D-ribose Hydrogel

    Participants assigned to this arm will apply 1 gram (2 fingertip units) of topical 2-Deoxy-D-ribose hydrogel once daily to the targeted scalp areas for 6 months.

    Drug: Topical 2-Deoxy-D-ribose Hydrogel

  • Active comparator
    Topical Minoxidil 5% Solution

    Participants assigned to this arm will apply topical minoxidil 5% solution to the targeted scalp areas for 6 months. Male participants will apply 1 cc twice daily, and female participants will apply 1 cc once daily.

    Drug: Topical Minoxidil 5% Solution

Interventions

  • DrugTopical 2-Deoxy-D-ribose Hydrogel

    Topical 2-Deoxy-D-ribose hydrogel prepared with sodium alginate. The hydrogel will be composed of sodium alginate, propylene glycol, 2-phenoxyethanol, and 2-Deoxy-D-ribose in water. Participants will apply 1 gram once daily to targeted scalp areas for 6 months.

  • Topical minoxidil 5% solution administered to targeted scalp areas for 6 months. Male participants will apply 1 cc twice daily, and female participants will apply 1 cc once daily.

06

What researchers measure

Primary outcomes

  1. Change in Terminal Hair Density

    Change in terminal hair density in the predefined trichoscopic assessment areas after 12 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group.

    Time frame: Baseline to Week 12

  2. Change in Total Hair Density

    Change in total hair density in the predefined trichoscopic assessment areas after 12 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group.

    Time frame: Baseline to Week 12

  3. Change in Tissue VEGF Level

    Change in tissue vascular endothelial growth factor (VEGF) levels from baseline to Week 12, measured using scalp biopsy specimens in both treatment groups.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Terminal Hair Density at Week 24

    Change in terminal hair density in the predefined trichoscopic assessment areas after 24 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group.

    Time frame: Baseline to Week 24

  2. Change in Total Hair Density at Week 24

    Change in total hair density in the predefined trichoscopic assessment areas after 24 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group.

    Time frame: Baseline to Week 24

  3. Global Photographic Assessment

    Change in standardized scalp photographs assessed independently by 3 blinded dermatologists using a 7-point modified physician global assessment scale ranging from -3 (significant disease progression) to 3 (excellent improvement).

    Time frame: Week 12 and Week 24

  4. Patient Global Assessment

    Participant-reported overall improvement using a 5-point scale: 0 = no improvement, 1 = mild response (less than 25%), 2 = moderate response (25% to 49%), 3 = good response (50% to 74%), and 4 = very good response (75% or more).

    Time frame: Week 12 and Week 24

  5. Patient Satisfaction Score

    Participant-reported treatment satisfaction using a 10-point visual analogue scale ranging from 0 (not satisfied at all) to 10 (completely satisfied).

    Time frame: Week 12 and Week 24

  6. Incidence of Treatment-Emergent Adverse Events

    Safety assessment of topical 2-Deoxy-D-ribose hydrogel based on adverse events, including erythema, itching, pain, allergic or irritant contact dermatitis, and undesirable hair texture, as evaluated through participant history, diary records, and clinical scalp examination.

    Time frame: Baseline to Week 24

  7. Correlation of Treatment Response With Clinical and Demographic Variables

    Association between treatment response and selected clinical and demographic variables collected during the study.

    Time frame: Baseline to Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this is a single-center study with a small sample size, and de-identification cannot be fully guaranteed. Aggregate results, including summary statistics and outcome analyses, will be made available through publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.

Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's planned 9 months is below that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Jan 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07502976
Responsible party
heba ahmed abdelgayed ibrahim (Lecturer of Dermatology, Kasr El Aini Hospital) — Principal investigator
First posted
Mar 31, 2026
Start date
Jan 1, 2026
Primary completion
Oct 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

HEBA AHMED
Contact
heba.a.abdelgayed@kasralainy.edu.eg
+201016532351

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion